-
Something wrong with this record ?
Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer
O. Tezcan, AS. Elshafei, K. Benderski, E. Rama, M. Wagner, D. Moeckel, R. Pola, M. Pechar, T. Etrych, S. von Stillfried, F. Kiessling, R. Weiskirchen, S. Meurer, T. Lammers
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Drug Resistance, Neoplasm MeSH
- Doxorubicin MeSH
- Humans MeSH
- Liposomes MeSH
- Drug Resistance, Multiple MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Tumor Microenvironment MeSH
- Breast Neoplasms * MeSH
- Polymers pharmacology MeSH
- Triple Negative Breast Neoplasms * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Multidrug resistance (MDR) reduces the efficacy of chemotherapy. Besides inducing the expression of drug efflux pumps, chemotherapy treatment alters the composition of the tumor microenvironment (TME), thereby potentially limiting tumor-directed drug delivery. To study the impact of MDR signaling in cancer cells on TME remodeling and nanomedicine delivery, we generated multidrug-resistant 4T1 triple-negative breast cancer (TNBC) cells by exposing sensitive 4T1 cells to gradually increasing doxorubicin concentrations. In 2D and 3D cell cultures, resistant 4T1 cells are presented with a more mesenchymal phenotype and produced increased amounts of collagen. While sensitive and resistant 4T1 cells showed similar tumor growth kinetics in vivo, the TME of resistant tumors was enriched in collagen and fibronectin. Vascular perfusion was also significantly increased. Fluorophore-labeled polymeric (∼10 nm) and liposomal (∼100 nm) drug carriers were administered to mice with resistant and sensitive tumors. Their tumor accumulation and penetration were studied using multimodal and multiscale optical imaging. At the whole tumor level, polymers accumulate more efficiently in resistant than in sensitive tumors. For liposomes, the trend was similar, but the differences in tumor accumulation were insignificant. At the individual blood vessel level, both polymers and liposomes were less able to extravasate out of the vasculature and penetrate the interstitium in resistant tumors. In a final in vivo efficacy study, we observed a stronger inhibitory effect of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin. These results exemplify that besides classical cellular MDR, microenvironmental drug resistance features should be considered when aiming to target and treat multidrug-resistant tumors more efficiently.
Institute of Macromolecular Chemistry Czech Academy of Science Prague Czech Republic
Institute of Pathology University Hospital RWTH Aachen Aachen Germany
UT Brown Foundation Institute of Molecular Medicine UTHealth Houston Houston TX USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004317
- 003
- CZ-PrNML
- 005
- 20230425141302.0
- 007
- ta
- 008
- 230418s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2022.12.056 $2 doi
- 035 __
- $a (PubMed)36599395
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Tezcan, Okan $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany.; UT Brown Foundation Institute of Molecular Medicine, UTHealth Houston, Houston, TX, USA. Electronic address: okan.tezcan@uth.tmc.edu
- 245 10
- $a Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer / $c O. Tezcan, AS. Elshafei, K. Benderski, E. Rama, M. Wagner, D. Moeckel, R. Pola, M. Pechar, T. Etrych, S. von Stillfried, F. Kiessling, R. Weiskirchen, S. Meurer, T. Lammers
- 520 9_
- $a Multidrug resistance (MDR) reduces the efficacy of chemotherapy. Besides inducing the expression of drug efflux pumps, chemotherapy treatment alters the composition of the tumor microenvironment (TME), thereby potentially limiting tumor-directed drug delivery. To study the impact of MDR signaling in cancer cells on TME remodeling and nanomedicine delivery, we generated multidrug-resistant 4T1 triple-negative breast cancer (TNBC) cells by exposing sensitive 4T1 cells to gradually increasing doxorubicin concentrations. In 2D and 3D cell cultures, resistant 4T1 cells are presented with a more mesenchymal phenotype and produced increased amounts of collagen. While sensitive and resistant 4T1 cells showed similar tumor growth kinetics in vivo, the TME of resistant tumors was enriched in collagen and fibronectin. Vascular perfusion was also significantly increased. Fluorophore-labeled polymeric (∼10 nm) and liposomal (∼100 nm) drug carriers were administered to mice with resistant and sensitive tumors. Their tumor accumulation and penetration were studied using multimodal and multiscale optical imaging. At the whole tumor level, polymers accumulate more efficiently in resistant than in sensitive tumors. For liposomes, the trend was similar, but the differences in tumor accumulation were insignificant. At the individual blood vessel level, both polymers and liposomes were less able to extravasate out of the vasculature and penetrate the interstitium in resistant tumors. In a final in vivo efficacy study, we observed a stronger inhibitory effect of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin. These results exemplify that besides classical cellular MDR, microenvironmental drug resistance features should be considered when aiming to target and treat multidrug-resistant tumors more efficiently.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a liposomy $7 D008081
- 650 12
- $a triple-negativní karcinom prsu $7 D064726
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a doxorubicin $7 D004317
- 650 _2
- $a mnohočetná léková rezistence $7 D018432
- 650 _2
- $a polymery $x farmakologie $7 D011108
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a nádory prsu $7 D001943
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Elshafei, Asmaa Said $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Benderski, Karina $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Rama, Elena $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Wagner, Maike $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Moeckel, Diana $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Pola, Robert $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
- 700 1_
- $a Pechar, Michal $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
- 700 1_
- $a Etrych, Tomas $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
- 700 1_
- $a von Stillfried, Saskia $u Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Kiessling, Fabian $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Weiskirchen, Ralf $u Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Meurer, Steffen $u Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Lammers, Twan $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany.. Electronic address: tlammers@ukaachen.de
- 773 0_
- $w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 354, č. - (2023), s. 784-793
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36599395 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141258 $b ABA008
- 999 __
- $a ok $b bmc $g 1924787 $s 1190526
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 354 $c - $d 784-793 $e 20230128 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- LZP __
- $a Pubmed-20230418